Compare Regeneron Pharmaceuticals Inc (REGN) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Clear Secure Inc trades at $43.42 (market cap $4.49B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.6× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.32%). Which is the better fit depends on your goals.
| REGN | YOU | |
|---|---|---|
Market Cap | $83.43B | $4.49B |
Sector | Health | Technology |
52-Week High | $852.03 | $62.36 |
52-Week Low | $555.51 | $29.61 |
Enterprise Value | $78.14B | $3.64B |
Dividend Yield | 0.46% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Clear Secure (YOU) trades at $43.6, down 1.65% on the day, amid a bearish technical signal. The company shows strong fundamental momentum with 27% year-over-year revenue growth in Q2 2026 and expanding profitability, though valuation ratios like a P/E of 29.46 appear elevated. Recent news highlights a strategic partnership with CrowdStrike and the launch of corporate memberships, signaling growth initiatives beyond airports.
The outlook is mixed: robust earnings beats and membership growth support upside, but high valuation and insider selling pose risks. Analyst consensus is evenly split between Buy and Hold, reflecting cautious optimism. Key near-term catalysts include Q3 2026 earnings and the success of new enterprise offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
